Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study

Neurobiology of Aging

Volumn 36, Issue 9, 2015, Pages 2587-2596

  Kruse, Niels ^a   Persson, Staffan ^b   Alcolea, Daniel ^c,d   Bahl, Justyna M C ^e   Baldeiras, Ines ^f   Capello, Elisabetta ^g   Chiasserini, Davide ^h   Bocchio Chiavetto, Luisella ^i,j   Emersic, Andreja ^k   Engelborghs, Sebastiaan ^l   Eren, Erden ^m   Fladby, Tormod ⁿ   Frisoni, Giovanni ^i,o   García Ayllón, María Salud ^d,p   Genc, Sermin ^m   Gkatzima, Olymbia ^q   Heegaard, Niels H H ^e,r   Janeiro, André M ^s   Kováčech, Branislav ^t   Kuiperij, H Bea ^u   Leitão, Maria J ^f   Lleó, Alberto ^c,d   Martins, Madalena ^s,v   Matos, Mafalda ^s   Mollergard, Hanne M ⁿ   Nobili, Flavio ^g   Öhrfelt, Annika ^b   Parnetti, Lucilla ^h   de Oliveira, Catarina Resende ^f   Rot, Uros ^k   Sáez Valero, Javier ^d,p   Struyfs, Hanne ^l   Tanassi, Julia T ^e   Taylor, Peggy ^w   Tsolaki, Magda ^q   Vanmechelen, Eugeen ^x   Verbeek, Marcel M ^u   Zilka, Norbert ^t   Blennow, Kaj ^b   Zetterberg, Henrik ^b,y   Mollenhauer, Brit ^a,z   more..

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^e STATENS SERUM INSTITUT   (Denmark)

^f UNIVERSITY OF COIMBRA   (Portugal)

^g Neurology Unit   (Italy)

^h UNIVERSITY OF PERUGIA   (Italy)

ⁱ IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^j ECAMPUS UNIVERSITY   (Italy)

^k UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^l UNIVERSITY OF ANTWERP   (Belgium)

^m DOKUZ EYLUL UNIVERSITY   (Turkey)

ⁿ AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^o UNIVERSITY OF GENEVA   (Switzerland)

^p MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^q ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^r ODENSE UNIVERSITY HOSPITAL   (Denmark)

^s Edificio Egas Moniz   (Portugal)

^t INSTITUTE OF NEUROIMMUNOLOGY   (Slovakia)

^u RADBOUD UNIVERSITY   (Netherlands)

^v INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^w BIOLEGEND   (United States)

^x ADX NEUROSCIENCES   (Belgium)

^y UNIVERSITY COLLEGE LONDON   (United Kingdom)

^z PARACELSUS ELENA KLINIK   (Germany)

more..

Author keywords

Alpha synuclein; Biomarker; Cerebrospinal fluid; ELISA; Validation

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER;

ALPHA SYNUCLEIN CEREBROSPINAL FLUID LEVEL; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CONTROLLED STUDY; DATA ANALYSIS; DEGENERATIVE DISEASE; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPEAN UNION; HUMAN; LABORATORY DEVICE; LABORATORY TEST; MATERIALS HANDLING; MEDICAL RESEARCH; METHODOLOGY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; STANDARDIZATION; VALIDATION STUDY; CEREBROSPINAL FLUID; CLINICAL TRIAL; EUROPE; FEMALE; INTERNATIONAL COOPERATION; MALE; MULTICENTER STUDY; PARKINSON DISEASE; REPRODUCIBILITY; UNITED STATES;

ALPHA-SYNUCLEIN; BIOMARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPE; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MALE; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; REPRODUCIBILITY OF RESULTS; UNITED STATES;

EID: 84940467315     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.05.003     Document Type: Article

References (27)

1. Aerts M.B., Esselink R.A., Abdo W.F., Bloem B.R., Verbeek M.M. CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol. Aging 2012, 33:430.
2. Cullen V.C., Fredenburg R.A., Evans C., Conliffe P.R., Solomon M.E. Development and advanced validation of an optimized method for the quantitation of Abeta42 in human cerebrospinal fluid. AAPS. J. 2012, 14:510.
3. Del Campo M., Mollenhauer B., Bertolotto A., Engelborghs S., Hampel H., Simonsen A.H., Kapaki E., Kruse N., Le Bastard N., Lehmann S., Molinuevo J.L., Parnetti L., Perret-Liaudet A., Saez-Valero J., Saka E., Urbani A., Vanmechelen E., Verbeek M., Visser P.J., Teunissen C. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark. Med. 2012, 6:419.
4. DeSilva B., Smith W., Weiner R., Kelley M., Smolec J., Lee B., Khan M., Tacey R., Hill H., Celniker A. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 2003, 20:1885.
5. Hall S., Ohrfelt A., Constantinescu R., Andreasson U., Surova Y., Bostrom F., Nilsson C., Widner H., Decraemer H., Nagga K., Minthon L., Londos E., Vanmechelen E., Holmberg B., Zetterberg H., Blennow K., Hansson O. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch. Neurol. 2012, 69:1445.
6. Hong Z., Shi M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Leverenz J.B., Baird G., Montine T.J., Hancock A.M., Hwang H., Pan C., Bradner J., Kang U.J., Jensen P.H., Zhang J. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010, 133:713.
7. Kasuga K., Tokutake T., Ishikawa A., Uchiyama T., Tokuda T., Onodera O., Nishizawa M., Ikeuchi T. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2010, 81:608.
8. Koel-Simmelink M.J., Vennegoor A., Killestein J., Blankenstein M.A., Norgren N., Korth C., Teunissen C.E. The impact of pre-analytical varaibles on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. J. Immunol. Methods 2014, 402:43.
9. Lee J.W., Devanarayan V., Barrett Y.C., Weiner R., Allinson J., Fountain S., Keller S., Weinryb I., Green M., Duan L., Rogers J.A., Millham R., O'Brien P.J., Sailstad J., Khan M., Ray C., Wagner J.A. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 2006, 23:312.
10. Lee H.J., Bae E.J., Jang A., Ho D.H., Cho E.D., Suk J.E., Yun Y.M., Lee S.J. Enzyme-linked immunosorbent assays for alpha-synuclein with species and multimeric state specificities. J. Neurosci. Methods 2011, 199:249.
11. Mattsson N., Andreasson U., Persson S., Arai H., Batish S.D., Bernardini S., Bernardini S., Bocchio-Chiavetto L., Blankenstein M.A., Carrillo M.C., Chalbot S., Coart E., Chiasserini D., Cutler N., Dahlfors G., Duller S., Fagan A.M., Forlenza O., Frisoni G.B., Galasko D., Galimberti D., Hampel H., Handberg A., Heneka M.T., Herskovits A.Z., Herukka S.K., Holtzman D.M., Humpel C., Hyman B.T., Iqbal K., Jucker M., Kaeser S.A., Kaiser E., Kapaki E., Kidd D., Klivenyi P., Knudsen C.S., Kummer M.P., Lui J., Llado A., Lewczuk P., Li Q.X., Martins R., Masters C., McAuliffe J., Mercken M., Moghekar A., Molinuevo J.L., Montine T.J., Nowatzke W., O'Brien R., Otto M., Paraskevas G.P., Parnetti L., Petersen R.C., Prvulovic D., de Reus H.P., Rissman R.A., Scarpini E., Stefani A., Soininen H., Schroder J., Shaw L.M., Skinningsrud A., Skrogstad B., Spreer A., Talib L., Teunissen C., Trojanowski J.Q., Tumani H., Umek R.M., Van Broeck B., Vanderstichele H., Vecsei L., Verbeek M.M., Windisch M., Zhang J., Zetterberg H., Blennow K. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011, 7:386.
12. Mollenhauer B., Cullen V., Kahn I., Krastins B., Outeiro T.F., Pepivani I., Ng J., Schulz-Schaeffer W., Kretzschmar H.A., McLean P.J., Trenkwalder C., Sarracino D.A., Vonsattel J.P., Locascio J.J., El-Agnaf O.M., Schlossmacher M.G. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 2008, 213:315.
13. Mollenhauer B., Schlossmacher M. Purification and quantification of neuronal alpha-synuclein: relevance for pathogenesis and biomarker development. Parkinsonś Disease: Molecular and Therapeutic Insights from Model Systems 2008, 559. Academic Press, New York, NY, USA. R. Nass, S. Przedborski (Eds.).
14. Mollenhauer B., El-Agnaf O.M., Marcus K., Trenkwalder C., Schlossmacher M.G. Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark. Med. 2010, 4:683.
15. Mollenhauer B., Locascio J.J., Schulz-Schaeffer W., Sixel-Doring F., Trenkwalder C., Schlossmacher M.G. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011, 10:230.
16. Mollenhauer B., Trautmann E., Taylor P., Manninger P., Sixel-Döring F., Ebentheuer J., Trenkwalder C., Schlossmacher M.G. Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci. Lett. 2013, 532:44.
17. Noguchi-Shinohara M., Tokuda T., Yoshita M., Kasai T., Ono K., Nakagawa M., El-Agnaf O.M., Yamada M. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res. 2009, 1251:1.
18. Ohrfelt A., Grognet P., Andreasen N., Wallin A., Vanmechelen E., Blennow K., Zetterberg H. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?. Neurosci. Lett. 2009, 450:332.
19. Park M.J., Cheon S.M., Bae H.R., Kim S.H., Kim J.W. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J. Clin. Neurol. 2011, 7:215.
20. Parnetti L., Chiasserini D., Bellomo G., Giannandrea D., De Carlo C., Qureshi M.M., Ardah M.T., Varghese S., Bonanni L., Borroni B., Tambasco N., Eusebi P., Rossi A., Onofrj M., Padovani A., Calabresi P., El-Agnaf O. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Mov. Disord. 2011, 26:1428.
21. Reesink F.E., Lemstra A.W., van Dijk K.D., Berendse H.W., van de Berg W.D., Klein M., Blankenstein M.A., Scheltens P., Verbeek M.M., van der Flier W.M. CSF alpha-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. J. Alzheimers. Dis. 2010, 22:87.
22. Spies P.E., Melis R.J., Sjogren M.J., Rikkert M.G., Verbeek M.M. Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. J. Alzheimers. Dis. 2009, 16:363.
23. Tateno F., Sakakibara R., Kawai T., Kishi M., Murano T. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2012, 26:213.
24. Tokuda T., Salem S.A., Allsop D., Mizuno T., Nakagawa M., Qureshi M.M., Locascio J.J., Schlossmacher M.G., El-Agnaf O.M. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 2006, 349:162.
25. Tokuda T., Qureshi M.M., Ardah M.T., Varghese S., Shehab S.A., Kasai T., Ishigami N., Tamaoka A., Nakagawa M., El-Agnaf O.M. Detection of elevated levels of {alpha}-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010, 75:1766.
26. Wang H., Wang K., Xu W., Wang C., Qiu W., Zhong X., Dai Y., Wu A., Hu X. Cerebrospinal fluid α-synuclein levels are elevated in multiple sclerosis and neuromyelitis optica patients during replase. J. Neurochem. 2012, 122:19.
27. Wennstrom M., Surova Y., Hall S., Nilsson C., Minthon L., Boström F., Hansson O., Nielsen H.M. Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One 2013, 8:e53250.